It is now well established that tumours undergo changes in cellular metabolism 1 . As this can reveal tumour cell vulnerabilities and because many tumours exhibit enhanced glucose uptake 2 , we have been interested in how tumour cells respond to different forms of sugar. Here we report that the monosaccharide mannose causes growth retardation in several tumour types in vitro, and enhances cell death in response to major forms of chemotherapy. We then show that these effects also occur in vivo in mice following the oral administration of mannose, without significantly affecting the weight and health of the animals. Mechanistically, mannose is taken up by the same transporter(s) as glucose 3 but accumulates as mannose-6-phosphate in cells, and this impairs the further metabolism of glucose in glycolysis, the tricarboxylic acid cycle, the pentose phosphate pathway and glycan synthesis. As a result, the administration of mannose in combination with conventional chemotherapy affects levels of anti-apoptotic proteins of the Bcl-2 family, leading to sensitization to cell death. Finally we show that susceptibility to mannose is dependent on the levels of phosphomannose isomerase (PMI). Cells with low levels of PMI are sensitive to mannose, whereas cells with high levels are resistant, but can be made sensitive by RNA-interference-mediated depletion of the enzyme. In addition, we use tissue microarrays to show that PMI levels also vary greatly between different patients and different tumour types, indicating that PMI levels could be used as a biomarker to direct the successful administration of mannose. We consider that the administration of mannose could be a simple, safe and selective therapy in the treatment of cancer, and could be applicable to multiple tumour types.
, so we considered that mannose might interfere with the uptake of glucose. In support of this hypothesis, we observed that mannose enhances levels of phosphorylated AMPK-a read-out of energy balance in cells 5, 6 (Extended Data Fig. 1e ). However, liquid chromatography coupled with mass spectrometry (LC-MS) analyses showed that levels of the phosphorylated form of the glucose analogue 2-deoxyglucose (2-DG-P)-used as a proxy for glucose uptake-did not correlate with mannose sensitivity in mannose-sensitive compared with mannoseinsensitive cell lines (Fig. 1a, b , Extended Data Fig. 1f, g ). In fact, mannose increased the intracellular pool of hexose-6-phosphate, which is produced in the first step of the metabolism of glucose and mannose (Extended Data Fig. 1h ). This effect was not observed with other sugars (Extended Data Fig. 1i ).
To determine whether the mannose-induced increase in hexose-6-phosphate levels is due to mannose or glucose, we performed LC-MS with an extended chromatography time to enable selective detection of the unphosphorylated form of these sugars. This revealed that mannose increased the intracellular pool of mannose, as expected, but it also increased the intracellular pool of glucose (Extended Data Fig. 1j, k) . To corroborate this finding, we treated cells with glucose labelled with two atoms of 13 C (1, (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) C 2 -glucose) and mannose labelled with six atoms of 13 C ( 13 C 6 -mannose) to enable detection due to differences in molecular mass; we again found that treatment with mannose increased intracellular levels of glucose (Extended Data Fig. 1l ).
As mannose did not reduce intracellular levels of glucose, but significantly affected cell growth, we considered that it might interfere with glucose metabolism. There is considerable crosstalk between the metabolism of these sugars, and mannose-6-phosphate can inhibit three enzymes that mediate glucose metabolism: hexokinases, phosphoglucose isomerase (PGI) and glucose-6-phosphate dehydrogenase 7 (Fig. 1d ). To address this possibility, we measured the levels of hexose-6-phosphate and lactate when cells were incubated in glucosefree medium supplemented with either 1,2-13 C 2 -glucose or 13 C 6 -mannose. This revealed that mannose accounts for more of the mannose-induced hexose-6-phosphate accumulation than does glucose, but also that glucose-6-phosphate is produced in the presence of mannose, albeit at lower levels when compared with cells treated with glucose alone (Fig. 1e) . We also observed that mannose produces only small amounts of lactate-indicating that it is poorly metabolised-and more notably, mannose markedly reduces the production of lactate from glucose ( Fig. 1f) . Further analysis revealed that mannose treatment not only affects pools of glycolytic intermediates, but also affects those involved in the tricarboxylic acid cycle, the pentose phosphate pathway and glycan synthesis ( Fig. 1g-i) . As with the effects on cell growth, these metabolic effects were not observed to the same extent with other sugars (Extended Data Fig. 1m-p) . Moreover, although mannose uptake was not lower in mannose-insensitive cells when compared to mannosesensitive cells (Extended Data Fig. 2a ), the effects of mannose on metabolism were only observed in cells sensitive to the sugar (Extended Data Fig. 2b-h ). We also found that mannose-induced AMPK phosphorylation does not occur concomitantly with changes in the levels of AMP or ATP, but is associated with a decrease in fructose-1,6-bisphosphate levels, as has been recently described 6 (Extended Data Fig. 3a-f ). Because mannose affects the growth of tumour cells, we questioned whether it can also affect the cellular response to chemothe rapeutic drugs. Although mannose alone did not affect cell viability, it significantly enhanced cell death when administered with cisplatin or doxorubicin-an effect not seen with other hexoses (Fig. 2a, b,  
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Extended Data Fig. 4a-c) . Mechanistically, the combination of mannose and the chemotherapeutic drug increased the levels of cleaved poly(ADP-ribose) polymerase (PARP, a substrate 8 of caspase-3) and this effect, together with cell death, was blocked by the pan-caspase inhibitor zVAD-FMK (Fig. 2c, d, Extended Data Fig. 4d ).
Because our data indicated that cell death after treatment with mannose and the chemotherapeutic drug is likely to proceed by apoptosis, we used CRISPR-Cas9 to determine which apoptotic pathways might be involved. Disruption of caspase 8 and FADD-two components of the extrinsic apoptotic pathway 9 -had no effect on cell death (Extended Data Fig. 4e-g ). By contrast, disruption of Bax and Bak-essential factors for mitochondrial outer membrane permeabilization and the intrinsic pathway 10 -markedly reduced cell death after treatment with mannose in combination with either cisplatin or doxorubicin (Fig. 2e, Extended Data Fig. 4h, i) .
As mitochondrial outer membrane permeabilization is controlled by members of the Bcl-2 family 11 , we examined the levels of these proteins in the presence of mannose, cisplatin or both in combination. In agreement with previous studies that detail a role for the Noxa/Mcl-1 axis in cell death induced by glycolysis inhibition and glucose deprivation [12] [13] [14] , we found that levels of Noxa increased after treatment with cisplatin and cisplatin plus mannose, and levels of Mcl-1 and Bcl-X L decreased after the combination treatment (Fig. 2f , Extended Data Fig. 4j ). Mechanistically, we consider that the change in Mcl-1 and Bcl-X L levels is due to decreased translation because the levels of the proteins themselves were still decreased in the presence of a proteasome inhibitor, and there was no change in the levels of their mRNAs, after the combination treatment (Extended Data Fig. 4k-m) . The involvement of these proteins was confirmed by CRISPR-mediated disruption of PMAIP1 (also known as NOXA) or by overexpression of Mcl-1 or Bcl-X L , which all suppressed cell death induced by mannose and chemotherapy (Fig. 2g, h, 5a ). Finally, we also observed that mannose enhances cell death induced by the Bcl-X L antagonist WEHI539, but not the Bcl-2 antagonist ).
We were keen to find out whether mannose also has effects in vivo. Tumour-bearing mice were given a single oral gavage of mannose, which resulted in a serum concentration of approximately 3 mM (Extended Data Fig. 6a Fig. 6d ).
To test whether mannose could affect tumour growth, mice were injected with tumour cells subcutaneously and were given mannose both freely in drinking water and three times a week by oral gavage. This did not affect the weight of the mice, nor did it visibly affect their health (Extended Data Fig. 6e ). However, it significantly inhibited tumour growth (Fig. 3b) , involving decreased numbers of BrdUpositive cells, which indicates that mannose inhibits cell proliferation both in vitro and in vivo (Extended Data Fig. 6f, g ).
We were also interested to know whether mannose can enhance chemotherapy in vivo. Tumour-bearing nude mice were treated with mannose and doxorubicin either alone or in combination. Although none of the treatments affected the weight or visibly affected the health of the mice (Extended Data Fig. 6h ), we found that either doxorubicin or mannose caused a reduction in tumour volume (Fig. 3c) . Moreover, an even greater effect was observed when doxorubicin was administered in combination with mannose (Fig. 3c) . Notably, when we examined the overall survival of the treated cohorts, those treated with doxorubicin plus mannose had a significantly increased life expectancy when compared to untreated mice or those treated with either doxorubicin or mannose alone (Fig. 3d) .
As our data indicated that mannose could potentially be used clinically, we wanted to understand why different cells vary in their sensitivity to the sugar. Because mannose affects several metabolic pathways, we reasoned that sensitivity may be connected to an apical enzyme involved in sugar metabolism. Our profiling revealed that mannose sensitivity was roughly inversely correlated with the levels and activity of PMI, the enzyme that catalyses the interconversion of mannose-6-phosphate and fructose-6-phosphate f, 7a) . Consequently, we knocked down MPI, the gene that encodes PMI, in three mannose-insensitive cell lines: SKOV3, RKO and IGROV1. In each case, MPI knockdown caused growth retardation upon mannose treatment (Fig. 4b , Extended Data Fig. 7b-g ) and markedly sensitized cells to cell death when mannose C 6 -m a n n o s e 1 3 C 6 -m a n n o s e (GLUT) and is phosphorylated into mannose-6-phosphate by hexokinases (HK). Mannose can then be used for glycosylation purposes or isomerized into fructose-6-phosphate by PMI; both PMI and PGI can also produce mannose-6-phosphate from glucose-6-phosphate. Mannose-6-phosphate also participates in the biosynthesis of deaminoneuraminic acid (KDN). Fruc, fructose; glc, glucose; man, mannose; TCA cycle, tricarboxylic acid cycle. e, f, Extraction of intracellular metabolites and measurement of the peak area per microgram of protein of glucose-6-phosphate (G6P) (m + 2) and mannose-6-phosphate (M6P) (m + 6) (e) and lactate (m + 0, m + 2, m + 3) (f), after 6-h incubation of U2OS-E1a cells in 10% dialysed FBS in glucose-free DMEM complete medium in the presence of 5 mM 1,2-13 C 2 -d-glucose alone, 5 mM 13 C 6 -d-mannose alone, or both sugars in combination. g-i, Relative amounts per microgram of protein of the intracellular metabolites glyceraldehyde-3-phosphate (GA3-P) (left) and phosphoenolpyruvate (PEP) (right) (g); α-ketoglutarate (α-KG) (left) and malate (right) (h); ribose-5-phosphate (ribose-5P) (left) and UDP-N-acetyl-glucosamine (UDP-GlcNAc) (right) (i) after a 6-h incubation of U2OS-E1a cells in 10% dialysed FBS in DMEM complete medium with 5 mM glucose, with or without 5 mM mannose as indicated. n = 3 independent experiments (a-c, g-i); data are representative of three independent experiments (e, f). Data are mean ± s.e.m. and were analysed by two-way ANOVA with Bonferroni correction (a-c) or paired two-tailed Student's t-test (g-i). *P < 0.05, **P < 0.01, ***P < 0.001.
was administered together with cisplatin (Fig. 4c) . Conversely, the overexpression of MPI in a mannose-sensitive cell line rendered the cell line refractory to the effects of mannose on both cell growth and cell death (Fig. 4d , Extended Data Fig. 7h-k) . Finally, we found that mannose treatment following MPI knockdown had highly significant effects on metabolic pathways downstream of the sugar (Fig. 4e , Extended Data Fig. 7l-o) .
We next questioned whether PMI could be modulated to affect the response of tumours to mannose in vivo. As the immune microenvironment is important in many therapeutic situations and because mannose can affect immune cell function 17, 18 , we decided to use immune-competent mice and two syngeneic cell lines (B16-F1 and LLC) that are ordinarily mannose-insensitive but become mannose-sensitive upon Mpi knockdown (Fig. 4f , g, Extended Data Fig. 8a-d) . In both cases, allografts formed with Mpi-knockdown cells were highly sensitive to the oral administration of mannose ( Fig. 4h-k) , without visibly affecting the health or weight of the mice (Extended Data Fig. 8e-h ).
We were keen to know whether PMI levels varied in human tumours, such that the analysis of PMI could potentially be used as a biomarker for mannose sensitivity. We therefore stained tissue microarrays containing sections from ovarian, renal, breast, prostate and colorectal cancers. This revealed that PMI levels not only varied among tumours from the same tissue, but also between tissues (Fig. 4l , Extended Data Fig. 9a ). PMI levels did not, however, have prognostic significance in breast and colon cancer, presumably because normal serum levels of mannose are low compared to glucose 19 (Extended Data Fig. 9b-d ). Most notable from our analyses was the fact that colorectal tumours generally have very low PMI levels (Fig. 4l) , which indicates that they may be broadly sensitive to mannose. To explore this, we used an inflammation-driven model of colorectal cancer and a genetically engineered mouse model driven by two genes that are frequently altered in this disease (Kras and Apc) 20 . In both models, mice maintained on drinking water containing 20% mannose had significantly fewer tumours at the clinical end point (Fig. 4m, n) , and notably, mannose had no negative effect on the health or weight of the mice over the time examined (Extended Data Fig. 9e, f) .
In contrast to its effects on glucose metabolism, mannose does not decrease the uptake of amino acids or fatty acids, and although mannose reduces glucose-dependent serine and glycine synthesis, this contributes only marginally to total cellular serine and glycine pools and Bcl-X L overexpressing) cells after 24 h treatment with or without 10 µM cisplatin and with or without 25 mM mannose. n = 3 independent experiments (a-c, e, g, h); data are representative of three independent experiments (d, f). Data are mean ± s.e.m. and were analysed by two-way ANOVA with Bonferroni correction (a-c, e, g, h). *P < 0.05, **P < 0.01, ***P < 0.001. Mice received either normal drinking water (control and doxorubicin) or 20% mannose in the drinking water (mannose and doxorubicin + mannose), plus the same treatment (either water or 20% mannose in water) via oral gavage three days a week. Doxorubicin treatment started on day 32 and mice received 5 mg kg −1 by intraperitoneal injection once a week. c, Tumour volume (mm 3 ) of all treatment groups. d, Graph representing the survival of the mice in all treatment groups until the end of the experiment at day 73. The number of mice for each experiment is as follows: n = 5 (−mannose), n = 4 (+mannose) (a); n = 10 (−mannose), n = 8 (+mannose) (b); n = 10 per group (c, d). Data are mean ± s.e.m. and were analysed by two-way ANOVA with Bonferroni correction (b, c) or log-rank test (two-sided Mantel-Cox test) (d). **P < 0.01, ***P < 0.001. Fig. 10a-f ). Mannose does not invoke an endoplasmicreticulum stress response, but affects transcription, translation and autophagy, although these effects were reversed by overexpression of MPI, which indicates that they are downstream of glucose metabolism (Extended Data Fig. 10g-l) . Moreover, the ablation of autophagy did not affect mannose sensitivity, showing that autophagy inhibition is not the mechanism underlying the effects of the sugar (Extended Data Fig. 10m , n). In summary, we conclude that mannose represents a well-tolerated means to interfere with glucose metabolism that could potentially be used clinically, either alone or in combination with other forms of cancer therapy.
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Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/s41586-018-0729-3. Kras G12D/+ mice were aged until the clinical end point. Mice were treated with normal drinking water or with 20% mannose in drinking water from four days post-induction until the clinical end point (n = 9 mice (−mannose), n = 8 mice (+mannose)). Tumours were counted in the colon of each mouse. n = 3 independent experiments (b, c, e, f); n = 5 independent experiments (d). Data represent one independent experiment performed in technical triplicate (g) or are representative of two independent experiments (a). Data are mean ± s.e.m. and are analysed by a one-sided Mann-Whitney U-test. ***P < 0.001. Data were analysed by two-way ANOVA with Bonferroni correction (c, e), multiple two-sided unpaired t-test with Holm-Sidak correction (d), two-way ANOVA with Tukey correction (h-k), one-way ANOVA with Bonferroni correction (l), unpaired two-tailed Student's t-test (m) and one-sided Mann-Whitney U-test (n). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Nat. Rev. Mol. Cell Biol. 11, 621-632 (2010 ) and penicillin (100 units per ml)-streptomycin (100 µg ml −1 ) (all from Life Technologies). U2OS-E1a cells were generated in our laboratory and have been previously described 21 . K562 cells were grown in RPMI-1640 and KP-4 cells were grown in IMDM (Life Technologies) with 20% FBS, supplemented with penicillin (100 units per ml)-streptomycin (100 µg ml
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). The B16-F1 mouse skin melanoma cell line was a gift from L. Machesky (Cancer Research UK Beatson Institute) and cells were maintained in DMEM (Thermo Fisher Scientific, 21969035) supplemented with 10% FBS (Thermo Fisher Scientific, 10270106), 2 mM l-glutamine (Thermo Fisher Scientific, 25030032), and penicillin-streptomycin (Thermo Fisher Scientific, 15140122). LLC mouse Lewis lung carcinoma cells were a gift from S. Zanivan (Cancer Research UK Beatson Institute) and were maintained in RPMI-1640 (Thermo Fisher Scientific, 31870074), 10% FBS, 10 mM HEPES (Thermo Fisher Scientific, 15630080), 2 mM l-glutamine and penicillinstreptomycin. These cell lines were confirmed to be free of mycoplasma.
Cells were transfected using calcium phosphate precipitates as previously described 16 . U2OS-E1a cells were infected with virus containing pBabepuro-empty or pBabe-puro-Bcl-X L following the same protocol as previously published
21
. U2OS-E1a cells were infected with virus containing pLZRS empty or pLZRS HA-Mcl-1 (provided by S. Tait)
22
. U2OS-E1a-infected cells were selected in DMEM 10% FBS containing 600 µg ml −1 of neomycin for 2 weeks. U2OS control and Bax/Bak CRISPR cells were provided by S. Tait.
The following siRNAs were used: PMI siRNA-1 (Dharmacon, J-011729-05-0002), pLX304 was a gift from D. Root (Addgene plasmid 25890). Human PMI cDNA was amplified using pCMV-Sport-MPI (Dharmacon, MHS6278-202802339) as a template and inserted into pDONR221 vector (Thermo Fisher Scientific, 12536017) using Gateway BP Clonase II Enzyme mix (Thermo Fisher Scientific, 11789020). PMI cDNA was then transferred into a pLX304 destination vector using Gateway LR Clonase II Enzyme mix (Thermo Fisher Scientific, 11791020). Lentivirus production and infection were carried out as described previously 24 . Cell culture treatments. Mannose treatment. Cells were seeded in six-well plates and incubated overnight at 37 °C. The following day, the medium was replenished with fresh full growth medium (DMEM, RPMI-1640 or IMDM) containing 25 mM d-mannose (DMEM or IMDM) or 11.11 mM d-mannose (RPMI-1640). Other sugars were added to a concentration of 25 mM: d-glucose (Sigma-Aldrich, G8270), d-fructose (Sigma-Aldrich, F3510), d-galactose (Sigma-Aldrich, G5388), l-fucose (Sigma-Aldrich, F2252 and Cayman Chemical, 16479). New stocks were prepared every two weeks of 1 M mannose in Milli-Q water and sterilized by filtering through a 0.22-µm pore filter. For control conditions, the same volume of Milli-Q water was added to the medium. Cells were left for at least 24 h for cell-death experiments or for 6 h for metabolic experiments. Cell death was blocked by treatment with zVAD-FMK (Apax Labs, A1902). Where indicated, cells were also treated with 2-deoxy-d-glucose (Sigma-Aldrich, D8375), tunicamycin (SigmaAldrich, T7765) or chloroquine (Sigma-Aldrich, C6628).
13
C-labelled sugars. The day after seeding, cells were washed three times with abundant PBS before adding glucose-free DMEM (supplemented with 10% dialysed FBS, 2 mM glutamine, 100 units per ml of penicillin and 100 µg ml −1 of streptomycin). Depending on the experiments, this medium could contain 5 mM of 1,2-13 C 2 -glucose alone, together with 13 C 6 -mannose or 5 mM 13 C 6 -mannose alone. Stocks of 1,2-13 C 2 -glucose and 13 C 6 -mannose were prepared at a concentration of 0.5 M in Milli-Q water before sterilization by filtering through a 0.22-µm pore filter. Chemotherapeutic drugs. Cells were plated overnight and then incubated for the indicated times in control or mannose-containing medium. After one day of incubation, fresh control and mannose-containing media were prepared and drugs were added as described for each experiment. The drugs used were cisplatin (SigmaAldrich, C2210000) and doxorubicin (Sigma-Aldrich, D1515). RT-qPCR. RT-qPCR was carried out as previously described 24 using primers for MCL1 (Qiagen, QT 00094122) and BCL2L1 (Qiagen, QT00997423). mRNA levels were determined by the relative standard curve method, normalized to 18S. Western blotting. Protein extraction was performed as previously described 25 . Protein lysates were separated by SDS-PAGE and blotted onto nitrocellulose membranes. Western blot analysis was performed according to standard techniques as previously described 25 . The following antibodies were used at a dilution of 1:1,000 unless otherwise stated: anti-β-actin (Abcam, ab8227), anti-Mcl-1 (Cell Signaling, 4572), anti-ERK2 (Santa Cruz, sc-154), anti-Bcl-X L (Cell Signaling, 2762), anti-HSP-90β (Santa Cruz, sc-1057), anti-PARP (Cell Signaling, 9542), anti-cleaved caspase-3 (Cell Signaling, 9664), anti-FADD (BD Transduction Laboratories, F36620), anti-caspase-8 (Cell Signaling, 4790), anti-Bax (BD Transduction Laboratories, 610983), anti-Bak (Cell Signaling, 6947), anti-Bim (Cell Signaling, 2993), anti-Noxa (Novus Biologicals, NB-600-1159), anti-phospho-AMPKα (Cell Signaling, 2535), anti-AMPKα (Cell Signaling, 5832), anti-PMI (Abcam, 128115), anti-LC3B (Cell Signaling, 2775S, 1:1,500), anti-β-actin (Cell Signaling, 4670S, 1:2,000), anti-ATG5 (Cell Signaling, 12994S), anti-ATG7 (Cell Signaling, 8558S), anti-Bip (also known as GRP78; Cell Signaling, 3177S) and anti-p62 (BD Biosciences, 610833, 1:2,000). Mouse PMI protein was detected using rabbit polyclonal PMI antibody (Proteintech, 14234-1-AP). Validation was based on information provided in the manufacturers' datasheets. In addition, as indicated in the manuscript, we used RNAi or CRISPR-Cas9 to validate the antibodies used to detect the following proteins: Bax, Bak, caspase-8, FADD, PMI, Atg5 and Atg7. Metabolic extraction of intracellular metabolites. Cells were seeded at a concentration of 100,000 cells per well in six-well plates. The next morning, the medium was replenished with fresh full medium and cells were kept under these conditions for another 24 h to stabilize their metabolism. Approximately 36-40 h after being plated, cells were treated under different conditions as described, using full growth medium or glucose-free medium in the presence or absence of unlabelled sugars or labelled sugars for 6 h. After a 6-h incubation at 37 °C, intracellular metabolites were extracted.
The medium was aspirated and six-well plates were placed on ice and washed thoroughly with 4 °C PBS three times before the addition of 500 µl extraction solvent (50% methanol, 30% acetonitrile, 20% Milli-Q water) to each well. Plates were then agitated at 4 °C for 5 min to successfully extract intracellular metabolites and then centrifuged at 16,100g for 10 min at 4 °C. Supernatants were transferred into HPLC vials and stored at −80 °C before LC-MS analysis.
An Exactive Orbitrap mass spectrometer (Thermo Scientific) was used together with a Thermo Scientific Accela HPLC system. The HPLC setup consisted of a ZIC-pHILIC column (SeQuant, 150 mm × 2.1 mm, 5 µm, Merck KGaA) with a ZIC-pHILIC guard column (SeQuant, 20 mm × 2.1 mm) and an initial mobile phase of 20% 20 mM ammonium carbonate, pH 9.4 and 80% acetonitrile. Cell extracts (5 µl) were injected and metabolites were separated over a 15-min mobile phase gradient, decreasing the acetonitrile content to 20%, at a flow rate of 200 µl min −1 and a column temperature of 45 °C. The total analysis time was 23 min. For longer runs of 37 min, a 30-min gradient with the same solvents was used, at a flow rate of 100 µl min −1 and a column temperature of 30 °C 26 . All metabolites were detected across a mass range of 75-1,000 m/z using the Exactive mass spectrometer at a resolution of 25,000 (at 200 m/z), with electrospray ionization and polarity switching to enable both positive and negative ions to be determined in the same run. Lock masses were used and the mass accuracy obtained for all metabolites was below 5 p.p.m. Data were acquired with Thermo Xcalibur software (version 2.2).
The peak areas of different metabolites were determined using Thermo TraceFinder software (version 3.2), in which metabolites were identified by the exact mass of the singly charged ion and by known retention time on the HPLC column. Commercial standards of all metabolites detected had been analysed previously on this LC-MS system with the pHILIC column. The 13 C labelling patterns were determined by measuring peak areas for the accurate mass of each isotopologue of many metabolites. Intracellular metabolites were normalized to the protein content of the cells, measured at the end of the experiment by the Lowry assay 27 . As the proteins precipitate upon addition of the metabolite extraction solvent, protein content was measured in the wells after the metabolites were extracted. Translation assay. Cells at 50% confluency were pretreated with or without 25 mM mannose for 24 h or with 100 µg ml −1 cycloheximide for 1 h. [ 35 S]methionine (1 MBq) (Perkin Elmer, EasyTag EXPRESS 35 S Protein Labelling Mix, NEG772002MC) was added to the culture medium (2 ml per well in a six-well plate) for 30 min. Cells were washed in ice-cold PBS, then lysed in lysis buffer (10 mM Tris pH 7.5, 50 mM NaCl, 0.5% NP40, 0.5% SDS, benzonase (Sigma-Aldrich E1014, 2 µl per 10 ml of lysis buffer)). Proteins were precipitated in 25% trichloroacetic acid at 4 °C for 30 min. The precipitates were washed on glass-fibre filters (Whatman 934-AH, 1287-024) with 70% ethanol followed by acetone, dried, and 5 cells. PMI enzymatic assay. Cells were grown to confluence, washed with PBS and collected by centrifugation (5 min, 150g at 4 °C). Cell pellets were lysed by three freeze-thaw cycles. Post-nuclear protein fractions (40 µg) were used to determine PMI activities in each cell line tested by means of a coupled enzymatic reaction. In brief, samples were incubated in a buffer containing 200 mU of PGI (Roche, 10 127 396 001), 500 mM glucose-6-phosphate dehydrogenase, 1 mM NADP + , 40 mM Tris-HCl pH 7.4, 6 mM MgCl 2 , 5 mM Na 2 HPO 4 /KH 2 PO 4 . Reactions were initiated by the addition of 1 mM mannose-6-phosphate, and the production of NADPH/H + was assessed for 2 h at room temperature by measuring the optical density at 340 nm (OD 340nm ). In parallel, western blots directed against PMI and ERK2 were performed to examine the correlation between PMI activities and PMI expression levels in each cell line analysed. Proteasome assay. Cells were seeded 24 h before 24-h treatments using media either with or without mannose supplementation (25 mM). A luminescence-based assay (Proteasome-Glo chymotrypsin-like cell-based assays, Promega) was performed according to the manufacturer's protocol. The measured proteasome activities were normalized to cell number by counting cells at the end of each experiment. Cells were treated with 10 µM MG132 as a control for the specificity of the assay. Lowry assay. The Lowry assay was used to determine the total protein content for each one of the triplicates from the metabolic experiments. First, 500 µl of solution A (70% Milli-Q water, 20% 5 M NaOH, 10% 2,5-dimethoxy-4-chloroamphetamine) was added to each well from a six-well plate and left under agitation for 20 min. Next, 5 ml of solution B (0.5 g NaCu-EDTA, 40 g Na 2 CO 3 , 8 g NaOH in 2 l) was added to each well and left for 40 min. Then, 500 µl of Folin reagent was added to each well and left for a minimum of 15 min until a blue colour was observed in each well. One or two six-well plates were used to construct a standard curve of protein concentration with BSA. Finally, 200 µl from each well was separately transferred to a 96-well plate and the absorbance was measured at 750 nm. The protein concentration was then measured by calculating the equation of the standard curve and extrapolating the absorbance of each well. Flow cytometry. Flow cytometry for unfixed cells (cell-death assay) was conducted as previously described 28 , and a FACSCalibur or ATTune NXT flow cytometer was used for the analysis. Animal experiments. All in vivo xenograft experiments were performed using six-week old female CD1-nude mice or C57/BL6J wild-type mice as approved by the Glasgow University Animal Welfare and Ethical Review Body and in accordance with UK Home Office guidelines. Mice were placed five per cage with free access to water and food (chow diet). Experimental cohort sizes were based on previous similar studies that have given statistical results while also respecting the limited use of animals in line with the 3R system: replacement, reduction, refinement. In no cases were mice maintained once the tumour size limit that was permitted in our Home Office license (15 mm in any direction) had been reached. All treatment studies were randomized, but did not involve blinding.
KP-4 cells (5 × 10 6 cells) were injected subcutaneously with 100 µl of Matrigel in either the right flank or both the left and the right flanks. LLC cells (1 × 10 6 cells) and B16-F1 cells (1 × 10 6 cells) were injected subcutaneously in 200 µl or 100 µl of PBS suspension, respectively. Mice were weighed and tumours were measured using callipers three times per week (usually on Monday, Wednesday and Friday of each week). The calculation of tumour volume was as follows: (L × S 2 )/2 (where L is the longest length and S is the shortest length).
For mannose treatment, normal drinking water was exchanged for 200 ml of 20% mannose in drinking water (w/v) and it was replaced once every week. Mice received mannose by oral gavage (200 µl) three times per week from the same stock of 20% mannose in water.
For doxorubicin treatments, each mouse received intraperitoneal injections at a concentration of 5 mg kg −1 once per week. Stocks of 1 mg ml −1 doxorubicin (Sigma-Aldrich, D1515) were prepared in Milli-Q water.
For azoxymethane (AOM) + dextran sodium sulfate (DSS) experiments, mice were injected with a single dose of AOM (Sigma-Aldrich, A5486) at 10 mg kg −1 . Five days after AOM injection, mice received three cycles of 1.5% DSS (MP Biomedical, 0216011080) in water; each cycle lasted five consecutive days, with one week in between each cycle. In the week between each cycle, mice received normal water or 20% (w/v) mannose water. After the last cycle of DSS, mice were maintained with normal water or mannose for two weeks before being killed on day 68.
Tissue collection. All mice were killed by CO 2 -mediated euthanasia 29 before collecting any tissue sample. Mice were placed in a cage and exposed to CO 2 for 100 s before neck dislocation.
Xenografted tumours were removed and detached from the skin and cut in half. One half of each tumour was fixed for 24-30 h in 10% neutral buffered formalin at room temperature. Formalin was then exchanged for 70% ethanol before histology.
The colons of mice from AOM + DSS carcinogenesis experiments were collected and fixed in formalin for histological processing.
For the experiments with the genetically engineered mouse model, Villin creER Apc fl/+ Kras G12D/+ mice 30 aged 6-12 weeks were given a single intraperitoneal injection of 80 mg kg −1 tamoxifen (Sigma-Aldrich, T5648). Four days post-induction, drinking water was exchanged for fresh drinking water or 20% mannose in drinking water (w/v) and given freely, this was replaced every week. Mice were aged until the clinical end point-when they displayed anaemia, hunching or weight loss. Colons were pinned out into 10% neutral buffered formalin and the number of tumours was counted. Blood sampling and blood metabolic extraction. To measure blood mannose levels, tail tipping was performed. Blood samples were directly frozen using dry ice and stored at −80 °C until metabolic extraction was performed.
For metabolic extraction of whole blood, 2-5 µl of each sample was diluted in 100-250 µl of metabolic extraction buffer on ice for 5 min (1:50 dilution). Then, all samples were centrifuged at 17,949g at 4 °C for 15 min. Finally, 100 µl of the supernatant from each sample was transferred into HPLC vials and stored at −80 °C until LC-MS analysis. PET and MRI scanning. Mice with KP-4 cells xenografts (n = 9, weight 24.6 ± 1.8 g) received either 200 µl of 20% w/v mannose in water (treatment group) or normal water (control group) by oral gavage 20 min before the injection of [
18 F]FDG. [
18 F]FDG (12.9 ± 1MBq) in 200 µl of normal saline was administered via an intravenous bolus injection in the tail vein. After an uptake phase of 30 min, PET and MRI scans were sequentially performed using a nanoScan (Mediso Ltd) PET/ MRI (1T) scanner. Mice were maintained under 2-2.5% isoflurane in medical air during the injection and imaging procedures. Static PET acquisitions were performed for 15 min, and subsequently whole body T1 GRE 3D Multi-FOV MRI scans (slice thickness 0.50 mm, repetition time (TR) 10 ms, echo time (TE) 2.3 ms, flip angle 12°) were performed to obtain anatomical references. For quantitative assessments of scans, regions of interest (ROI) were manually drawn around the edge of the tumour xenograft on MRI scans by visual inspection using PMOD software version 3.504 (PMOD Technologies) and the same ROI was copied on the respective PET scans. Tumour ROIs were slightly different between scans depending on the positions and angles of the mice on the scanner, therefore separate ROIs for each scan were drawn. The percentage injected dose per ml (%ID ml −1 ) was calculated using the formula %ID ml −1 = ROI activity (kBq ml −1 ) / injected dose × 100%. Data were reported as average %ID ml −1 ± s.d. Student's t-tests were used when comparing data between mannose-treated and control mice. Tissue microarray PMI staining. Tissue microarrays (TMAs) were first placed in xylene for 5 min before three washes of 1 min each (two in ethanol and one in 70% ethanol). TMAs were washed for 5 min in deionized water and then held for 25 min at 98 °C in a PT module using pH 6 sodium citrate retrieval buffer. They were further washed once in tris-buffered Tween (TbT) before blocking endogenous peroxidase for 5 min. TMAs were washed again using TbT and stained with PMI antibody (1C7, 1:50 dilution) for 1 h. TMAs were washed in TbT before and after incubation for 30 min in a mouse EnVision detection system. A 10-min incubation in 3,3′-diaminobenzidine tetrahydrochloride was then perfomed. TMAs were again washed with deionized water (1 min) before and after incubation with haematoxylin Z, followed by post-incubation with 1% acid alcohol. This was followed by a 30-s wash with deionized water, and then incubation with Scott's Tap Water substitute (1 min) and deionized water (1 min). BrdU staining. Xenografted tumours were embedded in paraffin, after which sections of an appropriate thickness were cut and kept at 60 °C overnight. Sections were first placed in xylene for 5 min before three washes of 1 min each (two in ethanol and one in 70% ethanol). Sections were washed for 5 min in deionized water and then held for 25 min at 98 °C in a PT module using pH 6 sodium citrate retrieval buffer. They were further washed once in TbT before blocking endogenous peroxidase for 5 min. Sections were washed in TbT before and after incubation with BrdU antibody (BD Biosciences 347580, 1:200 dilution) for 35 min. Sections were washed in TbT before and after incubation for 30 min in a mouse EnVision detection system. A 10-min incubation in 3,3ʹ-diaminobenzidine tetrahydrochloride was then perfomed. Sections were again washed with deionized water (1 min) before and after incubation with haematoxylin Z, followed by post-incubation with 1% acid alcohol. This was followed by a 30-s wash with deionized water, and then incubation with Scott's Tap Water substitute (1 min) and deionized water (1 min).
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Extended Data Fig. 1 | Mannose affects cell growth and metabolism. a, Growth curves of Saos-2 cells supplemented without (control) or with 25 mM of hexoses (man, mannose; gal, galactose; fru, fructose; fuc, fucose; glc, glucose). b-d, Growth curves of PA-TU-8902 (b) and A549 cells (d) in DMEM alone or with an additional 25 mM mannose; K562 cells in 10% FBS RPMI-1640 medium with or without 11.1 mM mannose (c). e, Western blots showing the levels of phospho-AMPKα (T172) and total AMPKα after 5, 15, 30 and 45-min incubation of U2OS-E1a with standard medium or medium supplemented with 25 mM mannose. f, Growth curves of SKOV3 and RKO cells in DMEM alone or with an additional 25 mM mannose. g, Levels (expressed as peak area per microgram of protein) of 2-deoxyglucose-phosphate (2-DG-P) in RKO, SKOV3, SAOS-2 and U2OS-E1a (U2OS) cells incubated with 10 mM 2-deoxyglucose for 6 h in the presence of 25 mM mannose in the culture medium (DMEM). Data are the average of three technical replicates and are representative of two independent experiments. h, Levels (measured as the percentage of peak area per microgram of protein, on a log 10 scale) of hexoses-6-phosphate (hexoses-6P) in U2OS-E1a cells after 6 h incubation in 10% dialysed FBS with 5 mM glucose in DMEM either with or without 5 mM mannose. i, Peak area per microgram of protein of hexoses-6-phosphate in U2OS-E1a cells incubated for 6 h in DMEM, with or without an additional 25 mM of the indicated sugars. j, k, Peak area per microgram of protein of intracellular non-phosphorylated mannose (j) or relative amounts of glucose (k) after a 6 h incubation of U2OS-E1a cells in 5 mM glucose in DMEM, with or without 5 mM mannose. l, Relative amount per microgram of protein of non-phosphorylated glucose m + 2 after 6 h incubation of U2OS-E1a cells in glucose-free DMEM either with 5 mM 1,2-13 C 2 -d-glucose alone or with 5 mM 1,2-13 C 2 -d-glucose and 5 mM 13 C 6 -d-mannose. m-p, Peak area per microgram of protein of glyceraldehyde-3-phosphate (GA3P) (m), phosphoenolpyruvate (PEP) (n), lactate (o) and UDP-GlcNAc (p) in U2OS-E1a cells after 6 h incubation in DMEM, with or without an additional 25 mM of the indicated sugars. n = 3 independent experiments (a-d, f, h-p) . Data are representative of two independent experiments (e). All data are mean ± s.e.m. and were analysed by one-way ANOVA (i, m-p), two-way ANOVA followed by Tukey's multiple comparisons (a) or paired two-tailed Student's t-test (h, j-l). *P < 0.05, **P < 0.01, ***P < 0.001.
Extended Data Fig. 4 | Mannose sensitizes cells to chemotherapyinduced cell death via the intrinsic apoptotic pathway. a, b a-c, e, f, h, l-o) . Data are representative of two independent experiments (g, j, k) or one experiment (i, p, q). In d, n = 3 independent experiments (each involving technical triplicates) (−zVAD-FMK) and n = 2 independent experiments (each involving technical triplicates) (+zVAD-FMK). All data are mean ± s.e.m. and were analysed by two-way ANOVA with Bonferroni correction (a-f, h, n, o). *P < 0.05, ***P < 0.001. 
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted All studies must disclose on these points even when the disclosure is negative.
Sample size
Experimental group/cohort sizes were based on previous similar studies that have given statistical results. For animals this also respected the limited use of animals in line with the 3R system: Replacement, Reduction, Refinement.
Data exclusions No data were excluded.
Replication
Where replication is indicated in the manuscript, the attempts at replication were successful.
Randomization For animal treatments, all studies were randomized.
Blinding
Yes, this was done for the Tissue Microarray (IHC) scoring.
Reporting for specific materials, systems and methods Obtaining unique materials The majority of materials are commercially available and materials generated by us will be available upon request.
Antibodies Antibodies used
The following antibodies were used at a 1/1000 dilution unless otherwise stated: β-Actin 
Authentication
The cell lines were not recently authenticated.
Mycoplasma contamination
All cell lines are routinely tested for mycoplasma and it is considered that the lines used in the study are mycoplasma free.
Commonly misidentified lines (See ICLAC register) No commonly misidentified lines were used in the study.
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals
Mice used in this study were 6-week old female CD1-nude mice (xenografts), 6-week old female C57/BL6J wild-type mice (allografts and AOM/DSS and 6-12 week old male and female C57/BL6J).
Wild animals
No wild animals were used in this study.
Field-collected samples
No field-collected samples were used in this study.
Flow Cytometry Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided. Gating strategy FSC/SSC were used to discern single cells from doublets/multiple cells. Samples without flourescent staining were used to establish boundaries between negative and positive cells.
Methodology
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
Magnetic resonance imaging
Experimental design
Design type
Sequential PET and MRI scans were performed in same session on a dual-modality PET/MRI scanner. MRI scans were performed to obtain anatomical reference for the quantification of positron emission tomography (PET) images.
Design specifications
For each mouse, static PET acquisitions were performed for 15 min and after that whole body T1-weighed GRE 3D
